CytoDyn’s (OTC: CYDY) Phase 2 Basket Trial for 22 Solid Cancer Tumors Treats First Patient with Leronlimab; Patient Enrollment Delayed Due to COVID-19
VANCOUVER, Washington, April 15, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]
